Evidence map›Paper›PMID 30514977›Full record

ArticleNature reviews. Clinical oncology2019

A framework for the development of effective anti-metastatic agents.

Robin L Anderson, Theo Balasas, Juliana Callaghan, R Charles Coombes, Jeff Evans, Jacqueline A Hall, Sally Kinrade, David Jones, Paul S Jones, Rob Jones and 9 more

Open access · hybridAbstract readConsensus Statement
PubMed Full text at PMC Publisher
In one paragraph

Article in Nature reviews. Clinical oncology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 186 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
186citing papers in PubMed, 2 pooled it
11.7field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

186 citing papers in PubMed, 2 syntheses or guidelines pooled it, 350 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Trial
  4. Trial
  5. Trial
  6. Article
  7. Review
  8. Therapeutic bacteria-trained NK cells confer long-term protection against cancer metastasis.Molecular therapy : the journal of the American Society of Gene Therapy · 2026
    Article
  9. Article
  10. Article
  11. Hierarchical Targeting of TREM2Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026
    Article
  12. Targeting extrachromosomal DNA in human cancers.Nature reviews. Drug discovery · 2026
    Review
  13. Article
  14. Review
  15. Article
  16. Article
  17. Review
  18. Review
  19. Review
  20. Article

126 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

19 authors at 11 institutions in 3 countries.

Robin L AndersonTranslational Breast Cancer Program, Olivia Newton-John Cancer Research Institute, Heidelberg, Victoria, Australia.
Theo BalasasCommercial Partnerships, Cancer Research UK (CRUK), London, UK.
Juliana CallaghanResearch and Innovation Services, University of Portsmouth, Portsmouth, Hampshire, UK.
R Charles CoombesDepartment of Surgery and Cancer, Imperial College London, Hammersmith Hospital, London, UK.
Jeff EvansInstitute of Cancer Sciences, University of Glasgow, Glasgow, Scotland, UK.
Jacqueline A HallResearch and Development, Vivacitv Ltd, Chesham, Buckinghamshire, UK.
Sally KinradeCancer Therapeutics Cooperative Research Centre (CTx), Melbourne, Victoria, Australia.
David JonesMedicines and Healthcare Products Regulatory Agency, London, UK.
Paul S JonesCentre for Drug Development, CRUK, London, UK.
Rob JonesInstitute of Cancer Sciences, University of Glasgow, Glasgow, Scotland, UK.
John F MarshallQueen Mary University of London, Barts Cancer Institute, London, UK.
Maria Beatrice PanicoMedicines and Healthcare Products Regulatory Agency, London, UK.
Jacqui A ShawLeicester Cancer Research Centre, University of Leicester, Leicester, Leicestershire, UK.
Patricia S SteegWomen's Malignancies Branch, Center for Cancer Research, National Cancer Institute, Bethesda, MD, USA.
Mark SullivanCancer Therapeutics Cooperative Research Centre (CTx), Melbourne, Victoria, Australia.
Warwick TongCancer Therapeutics Cooperative Research Centre (CTx), Melbourne, Victoria, Australia.
Andrew D WestwellSchool of Pharmacy and Pharmaceutical Sciences, Cardiff University, Cardiff, Wales, UK.
James W A RitchieCommercial Partnerships, Cancer Research UK (CRUK), London, UK. james.ritchie@cancer.org.uk.
Cancer Research UK and Cancer Therapeutics CRC Australia Metastasis Working Group
Primary Care Collaborative Clinical Trials Group · AUUniversity of Glasgow · GBCancer Research UK Technology · GBCardiff University · GBCenter for Cancer Research · USCenter for Global Development · USImperial College London · GBOlivia Newton-John Cancer Wellness & Research Centre · AUQueen Mary University of London · GBUniversity of Leicester · GBUniversity of Portsmouth · GB

Funding

Molecular Biology of the Metastatic PhenotypeZIASC000892 · NCI · DIVISION OF CLINICAL SCIENCES - NCI · PI STEEG, PATRICIA SCHRIVER · 2009 to 2023
$8.4M
Cancer Research UK 13462Cancer Research UK 18784Cancer Research UK 20276Cancer Research UK 20409Cancer Research UK 23464
6 · The paper itself

Abstract

Most cancer-related deaths are a result of metastasis, and thus the importance of this process as a target of therapy cannot be understated. By asking 'how can we effectively treat cancer?', we do not capture the complexity of a disease encompassing >200 different cancer types - many consisting of multiple subtypes - with considerable intratumoural heterogeneity, which can result in variable responses to a specific therapy. Moreover, we have much less information on the pathophysiological characteristics of metastases than is available for the primary tumour. Most disseminated tumour cells that arrive in distant tissues, surrounded by unfamiliar cells and a foreign microenvironment, are likely to die; however, those that survive can generate metastatic tumours with a markedly different biology from that of the primary tumour. To treat metastasis effectively, we must inhibit fundamental metastatic processes and develop specific preclinical and clinical strategies that do not rely on primary tumour responses. To address this crucial issue, Cancer Research UK and Cancer Therapeutics CRC Australia formed a Metastasis Working Group with representatives from not-for-profit, academic, government, industry and regulatory bodies in order to develop recommendations on how to tackle the challenges associated with treating (micro)metastatic disease. Herein, we describe the challenges identified as well as the proposed approaches for discovering and developing anticancer agents designed specifically to prevent or delay the metastatic outgrowth of cancer.

Indexed as

AnimalsAntineoplastic AgentsDrug DevelopmentHumansMolecular Targeted TherapyNeoplasm MetastasisUnited KingdomXenograft Model Antitumor AssaysAntineoplastic Agents

Identifiers

PMID30514977
PMCPMC7136167
OpenAlexW2902384546

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.